Toxic epidermal necrolysis induced by exposure to S,S-dimethyl cyanoimidodithiocarbonate: case report and nursing experience - Report - MDSpire

Toxic epidermal necrolysis induced by exposure to S,S-dimethyl cyanoimidodithiocarbonate: case report and nursing experience

  • By

  • Xue-Qing Liu

  • Xiao-Lan Dong

  • Yue-Tong Qian

  • Chang Shu

  • May 28, 2026

  • 0 min

Share

Clinical Report: Toxic Epidermal Necrolysis Triggered by DCT: A Case Study

Overview

This report details a case of toxic epidermal necrolysis (TEN) induced by S,S-dimethyl cyanoimidodithiocarbonate (DCT). The patient, with 60% body surface area involvement, underwent 20 days of intensive treatment and nursing care, resulting in significant improvement and discharge.

Background

Toxic epidermal necrolysis (TEN) is a severe dermatological condition characterized by extensive skin and mucosal detachment, often leading to high mortality rates. While drug-induced cases are common, TEN triggered by chemical agents like DCT is rare. Understanding the management of such cases is crucial for improving patient outcomes.

Data Highlights

ParameterValue
Body Surface Area Involvement60%
Duration of Treatment20 days
Maximum Temperature39.3 °C

Key Findings

  • The patient developed erythema and blisters after exposure to DCT.
  • Initial treatments at a local hospital were ineffective, leading to transfer for specialized care.
  • Intensive treatment included systemic glucocorticoids, cyclosporine, IVIG, and infliximab.
  • Personalized nursing care focused on skin integrity and infection prevention.
  • After 20 days, the patient showed nearly complete healing of skin lesions.

Clinical Implications

Effective management of TEN requires prompt recognition and withdrawal of the causative agent, along with multidisciplinary supportive care. Personalized nursing interventions are essential for maintaining skin integrity and preventing complications.

Conclusion

This case highlights the successful management of TEN triggered by a chemical agent, emphasizing the importance of tailored treatment and nursing care in improving patient outcomes.

Related Resources & Content

  1. Frontiers in Medicine, 2026 -- Rapid Progression to Toxic Epidermal Necrolysis Following Switch of PD-1 Inhibitors: A Case Report
  2. Frontiers in Medicine, 2026 -- Editorial: Exploring Cutaneous Drug-Related and Drug-Associated Adverse events: from Clinical Insights to Therapeutic Management
  3. Concurrent Toxic Epidermal Necrolysis and Acute Ulcerative Colitis: Distinct Disorder or Extraintestinal Manifestation?—A Case Study
  4. The ASCO Post -- Managing Toxicities Associated With Immunotherapy for Lung Cancer
  5. Stevens-Johnson syndrome/toxic epidermal necrolysis: initial assessment - PubMed
  6. External validation study of Re-SCORTEN in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis - PubMed
  7. Systemic immunomodulating therapies for epidermal necrolysis (Stevens-Johnson syndrome/toxic epidermal necrolysis): A systematic review and meta-analysis - PubMed
  8. Stevens-Johnson syndrome/toxic epidermal necrolysis: initial assessment - PubMed
  9. External validation study of Re-SCORTEN in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis - PubMed
  10. Systemic immunomodulating therapies for epidermal necrolysis (Stevens-Johnson syndrome/toxic epidermal necrolysis): A systematic review and meta-analysis - PubMed

Original Source(s)

Related Content